Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue

Dittadi, Ruggero; Gion, Massimo; Pagan, V.; Brazzale, Alessandra Rosalba; Maschio, O Del; Bargossi, A.; Busetto, A; Bruscagnin, G

doi:10.1038/bjc.1991.390

Cited by 26 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference between the mean concentration of EGFR in membrane fractions of tumor and normal tissue were insignificant (76.0+19.1 and 57.7_+10.1 fmol/ml protein, respectively). This finding agrees with previously reported hyperexpression of EGFR in tumors in comparison with normal lung [9,13,14]. However, a tendency (X2=3.27, p=0.07) toward a more frequent expression of EGFR in tumor tissues (75%) in comparison with normal tissue (68%) was revealed.…”

Section: Resultssupporting

confidence: 93%

Clinical and prognostic importance of expression of epidermal growth factor receptors in non-small-cell lung carcinoma

AIu

et al. 1999

Bull Exp Biol Med

View full text Add to dashboard Cite

Radioligand assay demonstrated that in patients with non-small-cell lung cancer, expression of epidermal growth factor receptors in the tumor is higher than in non-tumor tissue. Expression of epidermal growth factor receptors in tumor and non-tumor lung tissue does not correlate with the stage and metastasizing of the disease and tumor histology. It is also shown that expression of epidermal growth factor receptors in tumor and non-tumor tissue is associated with lower survival rate.Key Words: epidermal growth factor receptors; non-small-cell lung cancer; total and recurrence-free survival Lung cancer affects about one million people per year and is the most common cause of death among cancer patients in the majority of countries. It is now accepted that the outcome of treatment can be predicted by a number of clinical and morphological factors [2]. Biochemical parameters reflecting biological activity of tumor cells and tumor process in the whole are also very important.Previous studies of the mechanisms regulating tumor cell growth in the tracheobronchial tree demonstrated that lung cancer cells produce polypeptide growth regulators acting via a auto/paracrine mechanism [6][7][8]12,[15][16][17][18]. Among these polypeptides, epidermal (EGF) and transforming (a-TGF) growth factors are highly active and most studied regulators. These factors belong to the EGF-like peptide family and interact with common receptors on the membrane of target cells. It was shown that EGF control the growth of not only normal cells, but also their transformed malignant variants. This factor is a potent in vivo and in vitro mitogen tor epitheliocytes and connective tissue cells [3,4].Receptor of EGF (EGFR) is now considered as a prognostic tissue marker for tumors of various histogenesis [1,10]. However, despite extensive experimental and clinical investigation, the role of EGF-like peptides and their receptors in different tumors, in particular non-small-cell lung cancer (NSCLC) remained poorly understood. The aim of the present study was to evaluate the expression of EGFR in tumor and normal lung tissue and determine the importance of these parameters tor NSCLC prognosis. Sixty-three patients aged 22-78 years with NSCLC observed and treated at the MATERIALS AND METHODS Laboratory of Clinical

show abstract

Section: Resultssupporting

confidence: 93%

Clinical and prognostic importance of expression of epidermal growth factor receptors in non-small-cell lung carcinoma

AIu

et al. 1999

Bull Exp Biol Med

View full text Add to dashboard Cite

show abstract

“…Dittadi et al used a radioligand binding assay on 51 NSCLC and showed, like us, a significantly higher concentration of EGFr in tumours compared to normal lung (Dittadi et al, 1991). They found no relationship between histology or stage and receptor concentration.…”

Section: Discussionmentioning

confidence: 99%

The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival

Veale

Kerr²,

Gibson³

et al. 1993

Br J Cancer

202

111

View full text Add to dashboard Cite

show abstract

“…EGFR is expressed in the skin, liver, digestive tract and reproductive organs (36)(37)(38). The distributions of EGFR in various tissues can also be found at the human protein atlas (http://www.proteinatlas.org/).…”

Section: (A) Egfr Primary Tumor (3+) (B) Egfr Lymph Node Metastamentioning

confidence: 99%

Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

et al. 2012

View full text Add to dashboard Cite

Abstract. The epidermal growth factor receptor (EGFR) family members are potential targets for therapy using extracellular domain receptor binding agents, such as the antibodies trastuzumab and cetuximab, or antibodies labeled with therapeutically useful radionuclides or toxins. This is especially the case when the tumor cells are resistant to chemotherapy and tyrosine kinase inhibitors. Studies concerning the expression of these receptors in prostate cancer vary in the literature, possibly due to differences in patient inclusion, sample preparations and scoring criteria. In our study, EGFR, HER2 and HER3 expression was analyzed in prostate cancer samples from primary tumors and corresponding lymph node metastases from 12 patients. The expression of HER2 and EGFR was scored from immunohistochemical preparations and the HercepTest criteria (0, 1+, 2+ or 3+), while HER3 expression was scored as no, weak or strong staining. There were 5 EGFR-positive (2+ or 3+) primary tumors and 6 EGFR-positive lymph node metastases, and there was EGFR upregulation in one metastasis. Only 4 of the 12 patients had marked HER2 expression (2+ or 3+) in their primary tumors and there was one downregulation and 5 cases of upregulation in the metastases. Thus, a total of 8 out of 12 analyzed metastases were HER2-positive. Of the 12 primary tumors, 9 expressed HER3 while only 2 of the lymph node metastases expressed recognizable HER3 staining, so 7 metastases appeared to have downregulated HER3 expression.In one of the primary tumors there was positive co-expression of EGFR and HER2, while this co-expression was observed in 4 of the metastases. Thus, there were tendencies for upregulation of HER2, increased co-expression of EGFR and HER2 and downregulation of HER3 in the prostate cancer lymph node metastases in comparison to the primary tumors. The results are encouraging for studies involving more patients. Possible strategies for EGFR-and HER2-targeted therapy are briefly discussed in the present study, especially with regard to the expression and co-expression of EGFR and HER2 in metastases.

show abstract

Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue

Cited by 26 publications

References 25 publications

Clinical and prognostic importance of expression of epidermal growth factor receptors in non-small-cell lung carcinoma

Clinical and prognostic importance of expression of epidermal growth factor receptors in non-small-cell lung carcinoma

The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival

Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

Contact Info

Product

Resources

About